文献速递银屑病与炎症性皮肤病

新发银屑病的长期结局与预后:斯德哥尔摩银屑病队列研究

Long-term Outcomes and Prognosis in New-Onset Psoriasis.
PubMed 文献 · JAMA Dermatol · 2021-04-14

该研究基于斯德哥尔摩银屑病起始队列,纳入721例新发银屑病患者(病程<12个月),随访中位9.6年,旨在描述临床病程并识别长期结局指标。结果显示12年重度银屑病累积发生率为21%,10年后24%的患者有银屑病关节炎。斑块型、基线疾病活动度高于中位数及头皮受累者重度疾病风险高,外周附着点炎提示银屑病关节炎可能。

要点

  • 新发银屑病12年重度疾病累积发生率为21%。
  • 外周附着点炎患者10年后银屑病关节炎发生率达59%。
  • 早期系统治疗与10年后重度疾病风险降低相关。

核心结论

  • 临床特征组合与IL-23通路激活基因与银屑病病程显著相关。
  • 关节痛和外周附着点炎可能提示银屑病关节炎概率。

研究设计与样本

  • 斯德哥尔摩银屑病队列为非干预性起始队列研究,2001至2005年招募患者。
  • 共纳入721例病程<12个月、年龄15岁及以上新发银屑病患者。
  • 中位随访9.6年(IQR 8.8-10.4年),采用递归 partitioning 和回归模型识别长期结局指标。

主要发现

  • 12年重度银屑病累积发生率为21%。
  • 10年后509例临床检查患者中,斑块型20%(77/389)和滴状型48%(56/116)无治疗下疾病活动度极低,24%(120/509)有银屑病关节炎。
  • 斑块表型、疾病活动度高于中位数及头皮病变者重度疾病累积发生率为52%(95%CI 41%-64%),低于中位数者为11%(95%CI 8%-14%)。
  • 外周附着点炎患者10年后银屑病关节炎发生率为59%(48/82),无初始关节痛者为12%(37/304)(P<.001)。
  • 吸烟(HR 1.70;95%CI 1.10-2.63)和IL-23通路激活基因(OR 1.55;95%CI 1.14-2.11)与重度病程显著相关。

临床怎么用

  • 具有斑块表型、高疾病活动度、头皮病变或IL-23通路激活基因的患者需专科转诊和更密切随访。
  • 关节痛和外周附着点炎应评估银屑病关节炎可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis is a heterogeneous disease. Improved understanding of prognosis and long-term outcomes in new-onset psoriasis may improve care. OBJECTIVE: To describe the clinical course of psoriasis and identify possible indicators of long-term outcomes. DESIGN, SETTING, AND PARTICIPANTS: The Stockholm Psoriasis Cohort was a noninterventional inception cohort study enrolling patients between 2001 and 2005. The present study was conducted from January 15, 2019, to February 5, 2021. At enrollment and 10 years, patients were examined by dermatologists and rheumatologists. Data from examinations were complemented by questionnaires, medical records, and registers. A total of 721 patients with recent-onset psoriasis (<12 months duration), 15 years or older were recruited using advertising and referrals from a broad range of health care settings. MAIN OUTCOMES AND MEASURES: Disease severity and psoriatic arthritis (PsA). Recursive partitioning and regression models were implemented to identify probable indicators of long-term outcomes. RESULTS: A total of 721 patients (median [interquartile range] age, 39 [27-55] years; 405 [56%] women), including 542 (75%) with plaque-onset and 174 (24%) with guttate-onset psoriasis, were enrolled. The median follow-up was 9.6 years (interquartile range, 8.8-10.4 years). The cumulative incidence of severe psoriasis at 12 years from enrollment was 21%. Among 509 patients examined clinically after 10 years, 77 of 389 patients (20%) with plaque onset and 56 of 116 (48%) with guttate onset had minimal disease activity without treatment, and 120 of 509 (24%) had PsA. Recursive partitioning identified strata with distinct risks for severe skin disease and PsA: the cumulative incidence of severe disease in patients with plaque phenotype, above-median disease activity, and scalp lesions was 52% (95% CI, 41%-64%), compared with 11% (95% CI, 8%-14%) in patients with below-median disease activity at inclusion; and 48 of 82 patients (59%) with peripheral enthesitis had PsA after 10 years compared with 37 of 304 patients (12%) without initial joint pain (P < .001). Smoking (hazard ratio, 1.70; 95% CI, 1.10-2.63) and activating genes in the interleukin-23 (IL-23) pathway (odds ratio, 1.55; 95% CI, 1.14-2.11) were also significantly associated with a severe disease course. Systemic therapy at or before enrollment was associated with a lower risk for severe disease at 10 years compared with later initiation of systemic therapy (odds ratio, 0.24; 95% CI, 0.06-0.90). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that combinations of clinical characteristics at onset and activating genes in the IL-23 pathway are significantly associated with the clinical course of psoriasis, whereas joint pain and peripheral enthesitis may indicate the probability of PsA. Patients within those categories merit specialist referral and closer follow-up. The possibility of modifying the disease course with early systemic intervention should be tested.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Svedbom A, Mallbris L, Larsson P, et al. Long-term Outcomes and Prognosis in New-Onset Psoriasis. JAMA Dermatol. 2021. PMID: 33851956. doi:10.1001/jamadermatol.2021.0734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。